Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of IBD medications on COVID-19 outcomes: results from an international registry
Ryan C. Ungaro, Erica J. Brenner, Richard B. Gearry, et al.
Gut (2020) Vol. 70, Iss. 4, pp. 725-732
Open Access | Times Cited: 274

Showing 1-25 of 274 citing articles:

ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
Torsten Kucharzik, Pierre Ellul, Thomas Greuter, et al.
Journal of Crohn s and Colitis (2021) Vol. 15, Iss. 6, pp. 879-913
Open Access | Times Cited: 308
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting
Corey A. Siegel, Gil Y. Melmed, Dermot McGovern, et al.
Gut (2021) Vol. 70, Iss. 4, pp. 635-640
Open Access | Times Cited: 181
Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis
Anuraag Jena, Shubhra Mishra, Parakkal Deepak, et al.
Autoimmunity Reviews (2021) Vol. 21, Iss. 1, pp. 102927-102927
Open Access | Times Cited: 167
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study
Satveer K. Mahil, Katie Bechman, Antony Raharja, et al.
The Lancet Rheumatology (2021) Vol. 3, Iss. 9, pp. e627-e637
Open Access | Times Cited: 162
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
Nicholas A. Kennedy, James Goodhand, Claire Bewshea, et al.
Gut (2021) Vol. 70, Iss. 5, pp. 865-875
Open Access | Times Cited: 159
COVID-19 therapeutics: Challenges and directions for the future
Philip C. Robinson, David Liew, Helen Tanner, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 15
Open Access | Times Cited: 144
Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies
Serre-Yu Wong, Rebekah E. Dixon, Vicky Martinez Pazos, et al.
Gastroenterology (2021) Vol. 161, Iss. 2, pp. 715-718.e4
Open Access | Times Cited: 139
COVID‐19: immunopathology, pathophysiological mechanisms, and treatment options
Larissa E. van Eijk, Mathijs Binkhorst, Arno R. Bourgonje, et al.
The Journal of Pathology (2021) Vol. 254, Iss. 4, pp. 307-331
Open Access | Times Cited: 124
SARS-CoV-2 infection in patients with autoimmune hepatitis
Thomas Marjot, Gustav Buescher, Marcial Sebode, et al.
Journal of Hepatology (2021) Vol. 74, Iss. 6, pp. 1335-1343
Open Access | Times Cited: 110
Targeting TNF-α for COVID-19: Recent Advanced and Controversies
Yi Guo, Ke Hu, Yuxuan Li, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 105
COVID-19 and liver disease
Jean‐François Dufour, Thomas Marjot, Chiara Becchetti, et al.
Gut (2022) Vol. 71, Iss. 11, pp. 2350-2362
Closed Access | Times Cited: 71
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases
Paulina Núñez, Rodrigo Quera, Andrés Yarur
Drugs (2023) Vol. 83, Iss. 4, pp. 299-314
Open Access | Times Cited: 48
Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19
Zara Izadi, Erica J. Brenner, Satveer K. Mahil, et al.
JAMA Network Open (2021) Vol. 4, Iss. 10, pp. e2129639-e2129639
Open Access | Times Cited: 101
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments
Joel M. Gelfand, April W. Armstrong, Stacie Bell, et al.
Journal of the American Academy of Dermatology (2021) Vol. 84, Iss. 5, pp. 1254-1268
Open Access | Times Cited: 97
COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses
Filippo Fagni, David Simón, Koray Taşçılar, et al.
The Lancet Rheumatology (2021) Vol. 3, Iss. 10, pp. e724-e736
Open Access | Times Cited: 94
Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System
Nabeel Khan, Nadim Mahmud, Chinmay Trivedi, et al.
Gut (2021) Vol. 70, Iss. 9, pp. 1657-1664
Open Access | Times Cited: 72
SARS-CoV-2 and the Gastrointestinal Tract in Children
Maria Giovanna Puoti, Anna Rybak, Fevronia Kiparissi, et al.
Frontiers in Pediatrics (2021) Vol. 9
Open Access | Times Cited: 71
Systematic review with meta‐analysis: COVID‐19 outcomes in patients receiving anti‐TNF treatments
Georgios Kokkotis, Konstantina Kitsou, Ioannis Xynogalas, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 55, Iss. 2, pp. 154-167
Closed Access | Times Cited: 63
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper
Thomas Marjot, Christiane S. Eberhardt, Tobias Boettler, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 1161-1197
Open Access | Times Cited: 62
Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry
Ryan C. Ungaro, Erica J. Brenner, Manasi Agrawal, et al.
Gastroenterology (2021) Vol. 162, Iss. 1, pp. 316-319.e5
Open Access | Times Cited: 61
COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases
Rahul S. Dalal, Emma McClure, Jenna Marcus, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 19, Iss. 8, pp. 1730-1732.e2
Open Access | Times Cited: 58
Immunogenicity and Safety of Standard and Third‐Dose SARS–CoV‐2 Vaccination in Patients Receiving Immunosuppressive Therapy
Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, et al.
Arthritis & Rheumatology (2022) Vol. 74, Iss. 8, pp. 1321-1332
Open Access | Times Cited: 46
Failure to Achieve Target Drug Concentrations During Induction and Not HLA-DQA1∗05 Carriage Is Associated With Antidrug Antibody Formation in Patients With Inflammatory Bowel Disease
Elizabeth Spencer, Jordan Stachelski, Thierry Dervieux, et al.
Gastroenterology (2022) Vol. 162, Iss. 6, pp. 1746-1748.e3
Closed Access | Times Cited: 39
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy
Giuseppe Privitera, Daniela Pugliese, S. Onali, et al.
Autoimmunity Reviews (2021) Vol. 20, Iss. 6, pp. 102832-102832
Closed Access | Times Cited: 55
COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Kartikeya Tripathi, Gala Godoy Brewer, Minh‐Thu Nguyen, et al.
Inflammatory Bowel Diseases (2021) Vol. 28, Iss. 8, pp. 1265-1279
Open Access | Times Cited: 55
Page 1 - Next Page

Scroll to top